BiondVax

BiondVax Pharmaceuticals Ltd. was an Israeli biopharmaceutical company focused on developing and commercializing immunomodulation therapies and vaccines. Its lead product candidate was M-001, a universal influenza vaccine designed to protect against a broad range of seasonal and pandemic influenza strains.

M-001 was designed to stimulate cellular and humoral immune responses to conserved regions of the influenza virus, aiming to provide broader and longer-lasting protection than traditional seasonal influenza vaccines. The vaccine was comprised of nine conserved peptides from influenza A and B strains.

BiondVax conducted multiple clinical trials of M-001, including a pivotal Phase 3 clinical trial involving over 12,000 participants. While the trials demonstrated that M-001 was generally safe and well-tolerated, the pivotal Phase 3 trial did not meet its primary efficacy endpoint of statistically significant reduction in influenza illness.

Following the unsuccessful Phase 3 trial results, BiondVax announced that it was exploring strategic alternatives and seeking potential collaborations or partnerships. Ultimately, the company faced financial difficulties and ceased operations. While the company no longer exists, its research and development efforts, particularly concerning the universal influenza vaccine M-001, contributed to the broader scientific understanding of influenza immunology and vaccine development strategies.